0HUZ.L

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$4M	—	$-2.52	$-2.52–$-2.52	—	1
2027	$5M	+37.9%	$-1.82	$-1.82–$-1.82	—	1
2028	$12M	+112.6%	$-1.36	$-1.36–$-1.36	—	1
2029	$8M	-28.9%	$-1.21	$-1.21–$-1.21	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 8 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-11	$-0.87	$-0.54	+37.8%
2026-05-12	$-1.22	$-0.84	+30.9%
2026-03-31	$-1.41	$-1.24	+12.0%
2025-11-13	$-1.20	$-1.16	+3.2%
2025-08-18	$-4.14	$-1.87	+54.9%
2025-05-12	$-4.57	$-3.65	+20.0%
2025-02-27	$-4.67	$-3.26	+30.2%
2024-11-07	$-5.06

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
0HUZ.LImunon, Inc.	$0.88	-5.44%	$2M	—
0A4X.LDMK Pharmaceuticals Corporation	$0.00	+0.00%	$10	—
0H8E.LAccelerate Diagnostics, Inc.	$0.01	+0.80%	$25	—
0JDB.LInvitae Corporation	$0.00	-72.22%	$114597	—
0R02.LVivoSim Labs, Inc.	$0.26

Imunon, Inc.

Imunon, Inc. is a biotechnology enterprise operating at the clinical development stage, dedicated to the advancement and commercialization of innovative DNA-centric immunotherapeutic agents, vaccines, and targeted chemotherapy treatments. Its product pipeline prominently features GEN-1, a DNA-based immunotherapy specifically designed for the localized management of ovarian cancer. Alongside this, the company is developing ThermoDox, a proprietary liposomal formulation of doxorubicin that is activated by heat, currently being explored for various oncological indications. Beyond its specific product candidates, Imunon also possesses two early-stage platform technologies, which serve as foundational tools for crafting additional nucleic acid-based immunotherapies, vaccines, and diverse anti-cancer DNA or RNA therapeutics. Founded in 1982 and headquartered in Lawrenceville, New Jersey, the company was formerly recognized as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.

www.imunon.com

Employees: 20
IPO / List date: Jan 29, 2018
HQ: US

Held by traders on TradeandTell

No one on the platform currently holds 0HUZ.L.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in 0HUZ.L as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded 0HUZ.L yet.